Moderna stock fell after announcing that the European Medicines Agency approved its application for conditional marketing authorization (CMA), which sought authorization to use a 50-g booster dose of its bivalent BA.4/BA.5 Omicron-targeting COVID-19 vaccine, mRNA-1273.222, in people who are 12 years of age or older.
This bivalent vaccination is a mixture of 25-µg of Spikevax (mRNA-1273), Moderna (NASDAQ:MRNA) COVID vaccine that is now on the market, and 25-µg of another vaccine candidate targets the Omicron BA.4 and BA.5 sub variants. Together, they weigh 50-µg.
The submission is backed by data based on preclinical studies that were done on mRNA-1273.222 as well as data from the phase II/III research that examined mRNA-1273.214, which is another bivalent candidate developed by Moderna (NASDAQ:MRNA) to target the Omicron BA.1 subvariant.
All the major goals for the Omicron BA.1 targeted vaccination research conducted in phases II and III have been met. According to the research findings, individuals who were given a booster dosage of 50 mg of Spikevax produced low antibodies against the Omicron version compared to those who were given a dose of 50 mg of mRNA-1273.214. mRNA-1273.214 also induced significant neutralizing antibody responses against the Omicron subvariants BA.4 and BA.5 compared to those who got a booster dose of Spikevax. This was the case regardless of whether the individuals had a past infection or how old they were.
Moderna stock has dropped by 51.9% this year, which is far worse than the industry’s overall decrease of 28.0%.
Moderna’s stock price fell despite the European Medicines Agency accepting the company’s filing for an Omicron BA.4, BA.5 booster.
Featured Image – Unsplash © ianhutchinson92